Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost‐effectiveness analysis - Wu - 2018 - Journal of Diabetes Investigation - Wiley Online Library
Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge - In Suck Choi, Ie Byung Park, Kiyoung Lee, Tae Hoon
Which Inhibitor of the Renin–Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? | Circulation
Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension – An Update of the 2007 Report | Effective Health Care (EHC) Program
There's just been AKI. So what do we do with the ACEi/ARB? — NephJC
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) - ScienceDirect
JCM | Free Full-Text | Angiotensin Converting Enzyme Inhibitors versus Receptor Blockers in Patients with Ventricular Tachyarrhythmias
Cureus | Comparison Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Incidence of Lung Cancer: A Retrospective Study | Article
Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19 | Hypertension Research
ACE inhibitors and ARBs: Managing potassium and renal function | Cleveland Clinic Journal of Medicine
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial - The Lancet Respiratory Medicine
Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19 - The Centre for Evidence-Based Medicine
Understanding the renin–angiotensin–aldosterone–SARS-CoV axis: a comprehensive review | European Respiratory Society
ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking | Critical Care | Full Text
Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB | SpringerLink
Cross-Reactivity of ACE Inhibitor–Induced Angioedema with ARBs
Therapeutics Initiative | How do you prescribe ACEIs and ARBs for hypertension?
RACGP - ACEIs for cardiovascular risk reduction – have we taken our eye off the ball?
Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19 - The Centre for Evidence-Based Medicine
Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome | Journal of Translational Medicine | Full Text
Frontiers | Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitor in Combination with Angiotensin-Receptor Blocker in Chronic Kidney Disease Based on Dose: A Systematic Review and Meta-Analysis
Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19 | SpringerLink
Angiotensin converting enzyme inhibitors and incidence of lung cancer in a population based cohort of common data model in Korea | Scientific Reports
SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy - eBioMedicine
JCM | Free Full-Text | Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study
How effectively do ACE inhibitors and ARBs prevent migraines? | MDedge Family Medicine
A practical guide to antiproteinuric drugs in dogs
